Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma
Karen-Lise Garm Spindler, Morten Sørensen, Niels Pallisgaard, Rikke Andersen, Birgitte Mayland Havelund, John Ploen, Ulrik Lassen, Leif Anders Jakobsen
Dive into the research topics of 'Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma'. Together they form a unique fingerprint.